Introduction: until very recently, only small numbers of older patients with stroke had been recruited into randomised controlled trials of thrombolysis with recombinant tissue plasminogen activator (rt-PA) and patients aged >80 are excluded in the European licence for this therapy. We aimed to estimate the use and outcome of stroke thrombolysis in England across age groups, including the oldest-old. Methods: data were collected as part of the Stroke Improvement National Audit Programme. All adults receiving thrombolysis for acute ischaemic stroke as part of routine care between April 2010 and November 2011 were included. Multilevel multivariable logistic regression was used to analyse the associations between age, process of care and 30-day mortality. Results: of 37,151 adults admitted with acute ischaemic stroke, 3,374 (9.1%) received rt-PA. Patients aged >80 accounted for 21% of the thrombolysis recipients and 4.8% of patients in this age group received rt-PA. Treatment times were similar across all age groups, but older thrombolysis recipients were more likely to have Total anterior circulation infarct strokes and less likely to be functionally independent prior to stroke. Similar rates of post-thrombolysis complications were observed between patients aged >80 and younger patients. Mortality was high among older patients whether they were treated with rt-PA or not. Among patients treated with rt-PA, those aged 81-90 and >90 had, respectively, 34 and 270% higher odds of 30-day mortality than patients aged 70-80. Conclusion: treatment with rt-PA is now carried out frequently for older stroke patients in England. Their care is as timely as younger patients with no higher risk of major complication but mortality rates in older patients with stroke remain high.
Introduction
Thrombolysis using recombinant tissue plasminogen activator (rt-PA) is one of the main therapeutic interventions for acute stroke [1] . However, its benefit in patients over 80 years of age has been unclear [2] , despite the fact that this age group accounts for 30% of all strokes [3] . Moreover, increasing life expectancy will likely result in greater numbers of strokes in this age group, even while the overall incidence of stroke is falling [4, 5] . Until the recent publication of the results of the Third International Stroke Trial (IST-3) [6] , data on the efficacy of thrombolysis with rt-PA in older patients were limited largely to observational studies [7] [8] [9] [10] [11] , with only 79 patients over the age of 80 previously included in controlled trials [12, 13] . As a result, the European licence for the use of rt-PA in acute stroke management currently excludes patients >80 years of age, although no age limit is in place in the USA [14] . The evidence base for thrombolysis in the >80s has significantly increased following the recent publication of the IST3 trial, which demonstrated improved outcomes in >80s treated with rt-PA (27.3 versus 23.5% in the primary outcome of alive and independent at 6 months) [6] . We aimed to estimate the use and outcomes of thrombolysis as part of routine care in patients with acute ischaemic stroke, including older patients (aged >80) and the oldest-old (defined here as those aged >90).
Methods
Data were collected as part of the Stroke Improvement National Audit Programme (SINAP) which is a prospective national audit of the first 72 h of stroke care in England and Northern Ireland. The audit is managed by the Clinical Effectiveness and Evaluation Unit of the Royal College of Physicians and was established in 2010 to provide data concerning the quality of care provided to patients with acute stroke. Data on consecutive patients admitted to acute hospitals were abstracted from local care records and submitted to the audit via a secure web based tool. The web tool includes real-time data validation checks and records of individual episodes of care cannot be submitted to the audit until all data fields are completed. Audit data were linked to extracts from Hospital Episode Statistics (a nationally collected data set of hospital activity) and to a national register of death notifications [15] . Data linkage was carried out in accordance with information governance standards and no patient identifiable information was made directly available to the investigators. Full details of the audit and its data set are available online [16] .
All patients identified in the audit who were admitted in England with acute ischaemic stroke between 1 April 2010 and 30 November 2011 are included. Data from patients in Northern Ireland were not included because mortality data could not be linked for these. Patients receiving rt-PA as part of a clinical trial were not included in the main analyses. The Oxford Community Stroke Classification was used: Total Anterior Circulation Infarct (TACI), Partial Anterior Circulation Infarct (PACI), Lacunar Infarct (LACI) and Posterior Circulation Infarct (POCI) [17] . Post-thrombolysis complications were defined pragmatically; symptomatic intra-cranial haemorrhage (ICH) was defined as evidence of intracerebral haemorrhage on imaging in association with a clinically significant decline in neurological function.
Patient consent was not sought as all data were collected routinely as part of the SINAP national audit, though patients were able to request for their identifiable data not to be included. Permission to collect patient identifiers without explicit consent was granted by the Ethics and Confidentiality committee of the National Information Governance Board. Patients and patient representatives are involved in the design, reporting and oversight of SINAP. The SINAP audit is commissioned by the Healthcare Quality Improvement Partnership on behalf of the Department of Health in England and the Department of Health, Social Service and Public Safety for Northern Ireland.
Statistical analysis
Univariate hypothesis testing was performed using the Pearson Chi 2 test for categorical variables and the Kruskall-Wallis test for continuous variables. Confidence intervals for proportions were estimated using the Wilson score with continuity correction [18] . Odds ratios for mortality outcomes with analytic confidence intervals were estimated by fitting multilevel multivariable logistic regression models to adjust for case-mix. Covariates included in the models were sex, the presence of stroke-related neurological deficits (face, arm or leg weakness, hemianopia, inattention or neglect, brainstem or cerebellar signs, dysphasia, other), out of hours admission (weekend, public holiday or 6 p.m.-8 a.m. weekdays), pre-stroke independence (defined as modified Rankin Scale 0-1), reduced consciousness in the first 24 h and hypoxia (Sa02 <95% on air) in the first 24 h. Hospital level random effects were included to account for clustering at this level. The discrimination of the case-mix models were assessed using Receiver Operator Characteristic analysis and c-statistics. Sensitivity analyses were carried out to explore the effects of mortality in the first 3 days following admission (on the hypothesis that such early mortality is likely to be a marker of comorbidity or severity rather than reflect process of care). Calculation of power was performed to estimate the study to detect a difference in the proportion of patients with post-thrombolysis symptomatic ICH ( power 80%, α 0.05). All tests were two-tailed and P < 0.05 were considered to be significant in univariate and multivariate hypothesis tests. Analyses were carried out using STATA 11 (Statacorp).
Results
Data were provided by 123 hospitals (66% of eligible hospitals) in England admitting patients with acute stroke. Of these, 95 (77%) included data on patients receiving thrombolysis. Patients >80 years of age had been treated with thrombolysis in most (67/95; 71%) centres performing thrombolysis. Of 37,151 adults admitted with stroke, 38% (n = 14,147) were aged >80 years and 9.1% (n = 3374) received thrombolysis. Of these, 216 had received thrombolysis as part of a clinical trial and were excluded from further analysis. Only a minority (11.9%) of the >80 s treated with rt-PA did so as part of a clinical trial and 4.8% of patients in this age group were treated with rt-PA as part of routine care. Of the 3,158 patients receiving rt-PA as part of routine care, 671 (21.3%) were aged >80.
Baseline characteristics and unadjusted mortality rates for patients receiving thrombolysis are shown in Table 1 . There were no differences in the median door-to-needle times between age groups (P = 0.48) and in all groups the majority were treated with rt-PA within 3 h. In all age groups, patients receiving rt-PA were more likely to be functionally independent prior to their stroke and more likely to present with a TACI stroke compared with patients not treated with rt-PA. There were trends of an increasing prevalence of hypoxia, reduced consciousness in the first 24 h and 30-day mortality with older age (Chi 2 for trend; p < 0.0001 for both). Only in the 70-80 age group was there higher mortality among those treated with rt-PA (12.2 versus 8.7%; Chi 2 p = 0.0001). This difference persisted in a sensitivity analysis which excluded patients who died within 3 days of admission. The results of the age stratified case-mix adjusted analysis are shown in Table 2 . The discriminant ability of the fixed effects case-mix model was good, with a c-statistic of 0.85. For both those treated and those not treated with rt-PA, age was a strong risk factor for death: patients aged 81-90 treated with rt-PA had a 34% increased odds of death by 30 days compared with those aged 70-80. Similar trends were seen in those not treated with rt-PA. Treatment with rt-PA was associated with reduced case-mix adjusted odds of death for the 81-90 age group (adjusted odds ratio: 0.76, 95% CI: 0.60-0.98).
There were no significant differences in the rate of major complications (symptomatic ICH, angio-oedema or extra-cranial bleed) between those patients aged ≤80 and those >80 who received thrombolysis ( Table 3 ). The study had power at the 80% level and significance level of 0.05 to detect an absolute difference in the rate of symptomatic ICH between the two groups of >2.5% ; differences smaller than this therefore cannot be excluded. Mortality rates for symptomatic ICH were higher for patients aged >80 than those ≤80 (71 versus 36%, p = 0.005).
Discussion
Thrombolysis for older patients with stroke is already common practice in many stroke units in England; 21% of all patients receiving rt-PA for stroke in hospitals participating in SINAP were over the age of 80. Elderly patients had more extensive strokes and were less likely to be independent prior to stroke than patients ≤80 years of age but the care that they received was as timely as younger patients, with similar door-to-treatment times. Rates of postthrombolysis symptomatic ICH, angio-oedema and extracranial bleeds were no higher than in younger patients although mortality in older patients experiencing postthrombolysis ICH was higher than in younger patients. For both those treated with rt-PA and those who were not, 30-day mortality increased dramatically with age; 30-day mortality rates in the >90s were 10-fold those of patients aged 18-59. Although this analysis was not designed to test the effectiveness of rt-PA to modify outcomes, the case-mix adjusted analysis did not find strong evidence of a differential effect of age on 30-day mortality following rt-PA treatment. In conclusion, these analyses suggest that despite the licensing restriction of rt-PA in Europe, most hospitals in England performing stroke thrombolysis are treating selected older patients with rt-PA frequently, in a timely fashion and without significantly higher risk of major complication. These data are unable to address the question of the impact of this treatment on patients' functional outcomes.
Until the recent publication of IST3, data from randomised controlled trials concerning the use of rt-PA in older patients were limited to two cohorts, in which a total of 79 patients aged >80 were included [13] . Thrombolysis use in this cohort is thus largely informed by the outcomes Covariates in case-mix adjustment model a were sex, the presence of stroke-related neurological deficits (face, arm or leg weakness/sensory impairment, hemianopia, inattention or neglect, brainstem or cerebellar signs, dysphasia, other), out of hours admission, reduced consciousness level in the first 24 h, pre-stroke independence, hypoxia in the first 24 h and hospital level random effects. Case-mix model b did not include reduced consciousness in the first 24 h as a covariate but was otherwise specified identically.
reported in observational studies [7] [8] [9] [10] [11] . Although the majority (71%) of hospitals in this cohort were treating patients with ischaemic stroke >80 years of age with rt-PA, clinicians appear to be more selective in older age groups: only 5.6 and 2.5% of 81-90 and >90 s, respectively, received rt-PA compared with 10.4% in those aged 70-80. The effect of selection is illustrated by the higher proportion of patients independent pre-stroke (mRS 0-1) among rt-PA recipients, with the largest difference (17.1% absolute in the proportion of patients with pre-stroke mRS 0-1) occurring in those aged 81-90. It is reassuring that such selection does not result in delays in treatment for older patients, median door to needle times (60 min, IQR: 41-90) in the whole cohort are similar to those documented in SITS-MOST, which was drawn from the international SITS register [19] . Significant numbers of patients in all age groups (including the oldest-old) are, however, being treated with rt-PA beyond 3 h after symptom onset, and thus may be missing out on the extra benefit incurred by prompt treatment with rt-PA [6] .
The prevalence of major complications in our cohort was similar to those reported for patients aged ≤80 years of age in SITS-MOST [19] . In particular, rates of symptomatic ICH were no higher in those aged >80 years than in younger patients, a finding that is consistent with previous observational data in patients of this age, albeit from studies that have used a variety of different definitions of ICH [8] . However, this study was underpowered to detect an absolute difference in ICH rate of <2.5% and also used a less objectively defined definition of symptomatic ICH than other studies. Mortality following symptomatic ICH was twice as high in older patients, although the definition of symptomatic ICH used in this study was less objectively defined than in SITS. Rates of angio-oedema in elderly patients receiving rt-PA have not previously been specifically reported, but we observed rates that were similar for both age groups. The overall rate of angio-oedema in this cohort was lower than has previously been reported in several cohort studies (1.9%) [20, 21] , possibly reflecting variation in the recognition of this complication.
Mortality rates were high in those >80 years of age, even after excluding deaths in the first 3 days of admission that might be expected to reflect underlying co morbidity or stroke severity. However, older age is one of the most powerful independent predictors of mortality following ischaemic stroke [22] , and the higher mortality does not seem attributable to the major thrombolysis complications. Post-thrombolysis mortality rates in patients over >80 years of age have previously been shown to be very high, with in-hospital mortality rates of up to 35% [23] . Although data in this cohort cannot be used to draw conclusions about the effect of rt-PA on 30-day mortality (the treatment and control cohorts were not matched for significant covariates), the results of the multivariable analysis suggest that, however clinicians are selecting patients for rt-PA treatment, this is not resulting in a higher risk of 30-day mortality in elderly patients treated with rt-PA. Indeed, mortality odds are lower in those aged 81-90 treated with rt-PA, although this is most likely due to residual selection bias not accounted for in the multivariable analysis.
Strengths and limitations
As far as we are aware, this is the one of the largest cohort studies of patients >80 years receiving thrombolysis, second only to the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) [19] . Like SITS, this study has the advantage of describing the 'real world' outcomes of routine care and thus complements the findings derived from controlled trials. It is, however, different from SITS in a number of ways: this is a national cohort drawn from a country with a single payer universal healthcare system and is likely to contain less unmeasured inter-hospital heterogeneity in the organisation and delivery of healthcare than a multi-country register. In addition, this cohort also includes a large number of patients not in receipt of thrombolysis or neuroradiological intervention, enabling comparison between treated and untreated patients. Some hospitals provide data for both SITS and SINAP, and there will be some overlap in the cohorts.
Involvement in SINAP is voluntary and not all hospitals have participated for the same amount of time. Case ascertainment of stroke may vary between units and, although the very large size of the cohort included here mitigates this to some extent, it is not possible to exclude ascertainment bias in the sample. Unfortunately since the data had been collected with the primary purpose of reporting on the quality of acute care, neither baseline NIHSS scores or detailed information on the functional recovery of the majority of patients in this cohort are available. We have used discharge home as a proxy for functional recovery, although clearly this is less informative than structured assessments of post-stroke function and impairment.
Summary
Thrombolysis for ischaemic stroke in patients >80 years of age is already routine practice in many hospitals in England, despite the exclusion of this group of patients from the current European licence of rt-PA for stroke and until recently, an evidence base characterised by the inclusion of only small numbers of elderly patients in randomised controlled trials.
Rates of major thrombolysis complications are similar to younger patients, but mortality rates are high in all elderly patients with stroke whether they are treated with rt-PA or not. Further efforts to characterise which elderly patients are most likely to benefit from rt-PA and identify therapies that modify the age-related risks of early post-stroke mortality are important areas for further research.
